Home › Research › Treatments
Clinical Practice Outcomes With Lecanemab for Alzheimer Disease
Andy Liu, Alexander A. Moghadam, Mohammad Samsul Alam, Michael William Lutz, Amber Navarra, Sheng Luo, Li Wang, Jeffrey R. Petrella et al.. Neurology Open Access, 2026-08-07
Topic: Amyloid, tau and blood-test diagnosis
ε4 noncarriers and those with lower baseline amyloid burden. Despite the limitations of a single-site cohort, these findings inform real-world lecanemab safety and efficacy. Dual ARIA-E peaks at ~10 and ~25 weeks underscore the need for ongoing MRI monitoring. Although several markers showed modest negative predictive value, none reliably predicted ARIA. Improved markers to predict and monitor ARIA are needed to optimize cognitive outcomes.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Liu, A., Moghadam, A. A., Alam, M. S., Lutz, M. W., Navarra, A., Luo, S., et al. (2026). Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. Neurology Open Access. https://doi.org/10.1212/wn9.0000000000000121
Vancouver
Liu A, Moghadam AA, Alam MS, Lutz MW, Navarra A, Luo S, et al. Clinical Practice Outcomes With Lecanemab for Alzheimer Disease. Neurology Open Access. 2026. doi:10.1212/wn9.0000000000000121. PMID: 42746606.
BibTeX
@article{liu2026-42746606,
author = {Liu, Andy and Moghadam, Alexander A. and Alam, Mohammad Samsul and Lutz, Michael William and Navarra, Amber and Luo, Sheng and Wang, Li and Petrella, Jeffrey R. and others},
title = {{Clinical Practice Outcomes With Lecanemab for Alzheimer Disease}},
journal = {Neurology Open Access},
year = {2026},
doi = {10.1212/wn9.0000000000000121},
pmid = {42746606},
url = {https://doi.org/10.1212/wn9.0000000000000121}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- ε4 noncarriers and those with lower baseline amyloid burden.
- Despite the limitations of a single-site cohort, these findings inform real-world lecanemab safety and efficacy.
- Dual ARIA-E peaks at ~10 and ~25 weeks underscore the need for ongoing MRI monitoring.
- Although several markers showed modest negative predictive value, none reliably predicted ARIA.
- Improved markers to predict and monitor ARIA are needed to optimize cognitive outcomes.
Why it matters
This single-site real-world report describes lecanemab safety and effectiveness, noting two peaks of ARIA-E at about 10 and about 25 weeks that support ongoing MRI monitoring. No marker reliably predicted ARIA, and the authors call for better markers to optimize cognitive outcomes.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthModerate
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neurology Open Access) |
| Journal's citation record | 0 / 4 | Neurology Open Access: journal h-index 5 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Pudugramam Murali Doraiswamy: h-index 105 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of North Carolina at Chapel Hill: institution h-index 1,674 (OpenAlex) |
| Multi-centre collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42746606) |
| Free to read | 2 / 2 | Free to read |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1212/wn9.0000000000000121
- PubMed: 42746606
- Original source →
- Free full text: Neurology Open Access →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments
Also tagged “placebo-controlled”
783 studies in the library carry the topic tag “placebo-controlled”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.